Ads
related to: treatment for carcinoid tumors injection site diagram- Dosing & Administration
Healthcare Professionals: See How
Your Patients May Receive Treatment
- Identifying Patients
Discover Patient Identification &
IHC Info. Will You Take Action?
- Mechanism Of Action
MOA For A Therapy In Multiple
Metastatic Solid Tumor Types.
- Official Physician Site
Visit Site For A Treatment
Option For Metastatic Solid Tumors.
- Access Data & Results
View Data To See If A Treatment For
Metastatic Solid Tumors May Help.
- Request A Contact
Complete A Brief Form To Receive
Updates For A Treatment Option.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly.
177 Lu dotatate was approved in the United States for the treatment of SSTR positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults, in January 2018. [3] [6] [7] This was the first time a radiopharmaceutical had been approved for the treatment of GEP-NETs in the ...
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
It was previously used in the treatment of breast cancer, but has been replaced by more effective and less toxic agents. Estrace is an estrogen which was also formerly used for antiandrogen therapy of prostate cancer. [2] Polyestradiol phosphate is a long-acting derivative of estradiol that is applied as an intramuscular injection.
[25] [26] The safety and effectiveness of everolimus in carcinoid tumors have not been established. [25] [26] sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.
The most common originating site of carcinoid is the small bowel, particularly the ileum; carcinoid tumors are the most common malignancy of the appendix. Carcinoid tumors may rarely arise from the ovary or thymus. [6] They are most commonly found in the midgut at the level of the ileum or in the appendix.
Enterochromaffin cells, which give rise to carcinoid tumors, were identified in 1897 by Nikolai Kulchitsky and their secretion of serotonin was established in 1953 [105] when the "flushing" effect of serotonin had become clinically recognized. Carcinoid heart disease was identified in 1952, and carcinoid fibrosis in 1961. [105]
Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to neuroendocrine tumors (formerly known as carcinoid tumors). [1] The syndrome is caused by neuroendocrine tumors most often found in the gut releasing biologically active substances into the blood causing symptoms such as flushing and diarrhea, and less frequently, heart failure, vomiting ...
Ad
related to: treatment for carcinoid tumors injection site diagram